JAMA network open

Effectiveness of mRNA-1283 compared to BNT162b2 COVID-19 vaccines in older US veterans

Updated

Abstract

The mRNA-1283 vaccine was first used during the 2025-2026 respiratory virus season.

  • This vaccine targets key spike regions of the virus, which are important for immune response.
  • Older adults are at higher risk for severe outcomes related to COVID-19.
  • Data on vaccine effectiveness can help shape future seasonal vaccination strategies.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free